Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in serum institute of india

SII To Govt: Can Supply 1 Cr Doses of qHPV Vaccine Against Cervical Cancer

The phase 2/3 clinical trial of the vaccine has been completed with the support of the Department of Biotechnology. The government advisory panel NTAGI recently is learnt to have also approved the qHPV after reviewing the clinical trial data of the vaccine

Read More

SII In Talks With Bavarian Nordic For Importing Monkeypox Caccine

With only a handful cases of monkeypox in the country at the moment, he said for initiating local development of the vaccine SII would have to wait and watch for a few months to assess the real demand scenario. India has reported four cases monkeypox, including three in Kerala, so far

Read More

SII To Announce Indigenous Vaccine To Treat Cervical Cancer

The company had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age

Read More

SII Seeks Clearance To Export Covid Vaccine Covovax To US

According to a communication sent to the government by Prakash Kumar Singh, Director, Government and Regulatory Affairs at the SII, the shipment is likely to be dispatched on July 3 if due approval come in time, an official source told PTI. The sources said it will be the first instance of any Indian manufacturer's vaccine Covid or non-Covid to be exported to the US

Read More

SII's Covovax Gets DCGI's Nod For Emergency Use In Children Aged 7-11 Yrs

The drug regulator has also approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions

Read More

Indian Vaccine Manufacturer SII Plans African Plant

Africa was the only continent that did not have its own manufacturing capacity for COVID shots during the worst phases of the pandemic in the last two years, leaving it at the mercy of suppliers from overseas, including the SII

Read More

CCI Approves Serum Institute Life Sciences-Biocon Biologics Deal

Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator

Read More

Serum's Covavax Vaccine Now Available For 12-17 Age Group At Pvt Hospitals: Report

Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years

Read More

Covishield And Covaxin Doses To Cost Rs 225 Now In Private Hospitals

The Serum Institute of India has cut the rates of Covishield from ₹600 to ₹225 per dose, while Bharat Biotech has brought down the price of Covaxin from ₹1,200 to ₹225

Read More

India Has No Plans For Vaccine Booster: Sources

As vaccine supplies have increased, some doctors and public health experts in India have urged the government to start a booster programme for the most vulnerable like many Western nations have done.

Read More

Govt Allows Serum Institute To Export 50L Covishield Doses To 4 Nations

In addition to these three countries, the SII will also export Covishield to Bangladesh under COVAX, they said.

Read More

Serum Institute Buys 50% Stake In Pharma Packaging Firm Schott Kaisha

With this acquisition, Serum is securing its supply of high-quality pharma packaging amid rising global demand.

Read More

Vaccine Economy: Random Shots

Even though India has been grappling with the Covid -19 pandemic for more than a year now, its response to the myriad challenges including those pertaining to vaccine and vaccinations has left a lot to be desired

Read More

India Says Will Have 120 Million Vaccine Doses For Local Use In June

India has administered about 212 million doses, the most after China and the United States, but has given the necessary two doses to only about 3% of its 1.35 billion people.

Read More

Adar Poonawalla Exits Panacea Biotec; Sells Entire Stake For Rs 118 Crore

As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share, taking the total deal value to Rs 118.02 crore.

Read More